Vonoprazan

Phase 3

Phathom Pharmaceuticals, Inc. (PHAT)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q4 '27

PHATPhase 3$595M

Vonoprazan Phase 3 Est. Readout

Vonoprazan• Non-Erosive Gastro-Esophageal Reflux Disease500

Q4 2027~QEstimated

CT.gov

00%

Dec '26

PHATPhase 2$595M

Vonoprazan Phase 2 Est. Readout

Vonoprazan• Non-Erosive Gastro-Esophageal Reflux Disease80

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Non-Erosive Gastro-Esophageal Reflux Disease

View Full Landscape

Drug Information

Target Indication

Non-Erosive Gastro-Esophageal Reflux Disease

Clinical Trial

NCT05195528

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PHAT

Phathom Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

LansoprazolePhase 3

Erosive Esophagitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts